Page last updated: 2024-12-07

isoluminol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isoluminol is a cyclic hydrazide that exhibits chemiluminescence upon oxidation. It is typically used as a substrate for horseradish peroxidase (HRP), which catalyzes the oxidation of isoluminol in the presence of hydrogen peroxide, producing a blue light emission. Isoluminol is widely employed in various analytical and diagnostic applications, particularly in immunoassays and enzyme-linked immunosorbent assays (ELISAs). The chemiluminescence generated by isoluminol is highly sensitive, allowing for the detection of low concentrations of analytes. Isoluminol is also used as a probe in biological systems to study oxidative stress and the activity of reactive oxygen species (ROS). The chemiluminescent signal generated by isoluminol can be used to monitor the production of ROS in living cells and tissues, providing insights into oxidative stress-related diseases.'

isoluminol: chemiluminescent label [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID95014
CHEMBL ID14882
SCHEMBL ID28009
MeSH IDM0101393

Synonyms (40)

Synonym
nsc-13567
3682-14-2
nsc13567
mls002638327 ,
6-aminophthalazine-1,4-diol
4-aminophthalhydrazide
isoluminol
1ENU
DB02041
6-amino-2,3-dihydro-1,4-phthalazinedione
4-aminophthaloylhydrazine
smr001547813
bdbm50125767
6-amino-2,3-dihydro-phthalazine-1,4-dione
CHEMBL14882 ,
6-amino-2,3-dihydrophthalazine-1,4-dione
AE-562/42999240
HMS3086N23
A823382
nsc 13567
5id1912ana ,
1,4-phthalazinedione, 6-amino-2,3-dihydro-
unii-5id1912ana
iso-luminol
FT-0617600
AKOS015916424
TD8096
SCHEMBL28009
6-amino-phthalazine-1,4-diol
6-amino-2,3-dihydro-1,4-phthalazinedione #
AKOS024374898
AC-33250
mfcd00010560
Q27093128
AS-19110
DTXSID70958029
7-amino-4-hydroxyphthalazin-1(2h)-one
CS-W017373
HY-W016657
SY057321
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TRNA-GUANINE TRANSGLYCOSYLASEZymomonas mobilisKi8.30008.30008.30008.3000AID977610
Chain A, QUEUINE TRNA-RIBOSYLTRANSFERASEZymomonas mobilisKi8.30008.30008.30008.3000AID977610
Queuine tRNA-ribosyltransferaseZymomonas mobilis subsp. mobilis ZM4 = ATCC 31821Ki8.30000.60004.45008.3000AID228037
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID228037Inhibitory activity against eubacterial tRNA guanine transglycosylase (TGT) from Zymomonas mobilis2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1811Experimentally measured binding affinity data derived from PDB2001Journal of molecular biology, Feb-23, Volume: 306, Issue:3
A new target for shigellosis: rational design and crystallographic studies of inhibitors of tRNA-guanine transglycosylase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2001Journal of molecular biology, Feb-23, Volume: 306, Issue:3
A new target for shigellosis: rational design and crystallographic studies of inhibitors of tRNA-guanine transglycosylase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (35.48)18.7374
1990's8 (12.90)18.2507
2000's17 (27.42)29.6817
2010's13 (20.97)24.3611
2020's2 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.64 (24.57)
Research Supply Index4.32 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index33.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other72 (97.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]